Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sangamo Therapeutics
Biotech
PTC bets $211M on ‘special opportunity’ to enter Fabry market
PTC outbid Astellas and TerSera for Sangamo's near-approval gene therapy.
Nick Paul Taylor
Aug 13, 2026 8:15am
Sangamo enters bankruptcy, reveals asset sales with 2 pharmas
Jun 23, 2026 10:57am
Cash-strapped Sangamo seeks partner for new gene therapy
Jun 24, 2025 11:53am
Lilly saves gene therapy biotech with $18M upfront deal
Apr 3, 2025 6:00pm
Pfizer crashes Sangamo's stock by ending hem A gene therapy pact
Jan 2, 2025 6:08am
Astellas pays Sangamo $20M to boost neurological gene therapies
Dec 19, 2024 7:13am
